Growth Holds, But Profits Lag — Execution on New Units Is the Tell

Concord hit its growth target — revenue at ₹309.1 crore, up 25.1% year-on-year, meeting the >25% guidance issued at the start of FY27. That's the headline. But underneath, the quarter reveals a sharp and widening gap between top-line momentum and bottom-line delivery. PAT grew only 10.3%, leaving a 15-percentage-point spread. That gap is the story.

Gross margin fell to 76.2% from approximately 79.1% in the prior year quarter—a 290-basis-point contraction. Management attributes this to raw material inflation (solvents, power, fuel costs) and geopolitical supply chain disruptions. The company frames these as temporary, but the call exposed no clear timeline for recovery and no alternative sourcing disclosed. Worse, the compression is landing precisely as new facility depreciation (injectables at Unit-IV, Stelton U.S. formulations) is starting to drag on EBITDA. EBITDA margins held flat at 33.8% (stable versus the 33.0% run-rate in H1), masking the gross-margin damage through cost discipline and the still-immaterial drag from low-utilization new units. But this is a short-term cushion, not a structural solution.

The last claim is the one that slipped. Management's prior guidance (from Q1 FY27) was a 40% EBITDA margin target by FY28. On this call, that became a 38%–40% range over the next few years—a deliberate downgrade and timeline extension, driven by Stelton (U.S. formulation subsidiary) and injectables facility (Unit-IV) scaling more slowly than originally modeled. Stelton is still in the material-supply phase; injectables utilization sits at just 5%, with customer audits ongoing and contracts 'expected to materialize in H2.' The company is being honest about the risk, but the credibility of the recovery narrative now depends on execution in the coming two quarters.

Downgrade: EBITDA margin target timeline extended from FY28 to 'over next few years'; new facility ramp is slower than modeled. Downgrade: Formulation revenue grew only 6% in Q2, well below the company's 25% average—management cites customer procurement shift from formulations to APIs for emerging markets, a structural headwind. Upgrade: API growth remained robust at 30% YoY; immunosuppressants and oncology (nearly doubled YoY) are capturing market share. Domestic API grew 42%, signaling new customer wins. New: Inspira dermatology division launched with a quantified ₹5,000-crore India market TAM and a target of ₹400–500 crore revenue over 4–5 years. Neutral: Injectable facility TAM remains ₹5,000 crore with ₹300 crore top-line potential over 3–4 years, but customer contracts remain in audit phase with material ramp expected only in H2.

The stock is at ₹1,163.5, trading 56.3% below its all-time high and below all major moving averages (SMA20: ₹1,312.68; SMA50: ₹1,412.06; SMA200: ₹1,266.98). RSI at 34.1 signals a neutral-to-oversold technical setup. Trading volume is increasing, consistent with market re-engagement after a sustained drawdown. This matters: the stock has already priced in deep skepticism. The market is not buying the growth story or the margin recovery thesis. FII ownership has declined to 7.52% (down from 9.11% a year ago and down 0.28 percentage points sequentially). DII ownership is stable at 9.36%. Promoter holding remains unchanged at 44.08%. The FII sell-off, combined with a -56% drawdown from ATH, signals that institutional investors have already voted no on the near-term risk-reward. For a buyer, the question is whether new facility execution in H2 and margin recovery have enough upside from here to justify re-entry.